Journal of Renal Nutrition
Volume 15, Issue 2 , Pages 225-230, April 2005

L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients

  • Vincenzo Savica, MD

      Affiliations

    • University of Messina, Messina, Italy
    • Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy
  • ,
  • Domenico Santoro, MD

      Affiliations

    • University of Messina, Messina, Italy
    • Corresponding Author InformationAddress reprint requests to Domenico Santoro, University of Messina, Division of Nephrology, c.da Conte Coop. Sperone is. 3/E, 98168 Messina, Italy
  • ,
  • Giampiero Mazzaglia, MD

      Affiliations

    • Health Search, Italian College of General Practitioners, Messina, Italy
  • ,
  • Franco Ciolino, MD

      Affiliations

    • Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy
  • ,
  • Paolo Monardo, MD

      Affiliations

    • Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy
  • ,
  • Menotti Calvani, MD

      Affiliations

    • Scientific Department, Sigma-Tau, Rome, Italy
  • ,
  • Guido Bellinghieri, MD

      Affiliations

    • University of Messina, Messina, Italy
  • ,
  • Joel D. Kopple, MD

      Affiliations

    • Division of Nephrology and Hypertension and Research and Education Institute, Harbor-UCLA Medical Center, Torrance, CA, USA and the David Geffen School of Medicine and the School of Public Health at UCLA, Los Angeles, CA, USA

Scattered reports indicate that L-carnitine may suppress proinflammatory cytokines in sick individuals without renal disease and may improve protein synthesis or nitrogen balance either in patients without renal disease or in maintenance hemodialysis (MHD) or chronic peritoneal dialysis patients. We conducted an experimental study in MHD patients to evaluate the effects of L-carnitine treatment on inflammatory and protein-energy nutritional status. MHD patients were assigned to receive intravenous injections of L-carnitine 20 mg/kg (n = 48) or placebo (n = 65) thrice weekly at the end of each hemodialysis treatment for 6 months. The carnitine-treated group showed a statistically significant decrease in serum C-reactive protein and increase in serum albumin and transferrin, blood hemoglobin, and body mass index. Conversely, in the placebo-treated group, a significant decrease was reported for serum albumin, serum transferrin, and body mass index, whereas the other considered measures did not change significantly. These preliminary findings suggest that in MHD patients, L-carnitine therapy may suppress inflammation, particularly among those patients with C-reactive protein ≥3 mg/dL, and may improve protein-energy nutritional status.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1051-2276(04)00250-X

doi:10.1053/j.jrn.2004.10.002

Journal of Renal Nutrition
Volume 15, Issue 2 , Pages 225-230, April 2005